Abbott tests the power of a Big Pharma name with international branding push

Abbott Laboratories ($ABT) is already one of the biggest drugmakers in emerging markets. But with growing competition there from Big Pharma and plenty of smaller companies, Abbott wants to make sure its products stay in the forefront. So, it's rolling out a new branding campaign to cozy up with consumers and amp up its international name recognition. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.